$MRK

ADC Therapeutics reported a strong quarterly performance in Q4 2025, exceeding analysts' earnings expectations. The company highlighted increased demand for its latest drug, which has driven revenue growth significantly. Despite some concerns about regulatory hurdles, management expressed confidence in their pipeline. Overall, the results were positively received in the market, indicating potential for future growth. Analysts adjusted their price targets upward following the announcement.

Johnson & Johnson (JNJ) has released promising results from its Phase 1b clinical trial for a new cancer treatment. The data shows improved efficacy and safety profiles compared to existing therapies. This news has generated positive sentiment among investors, boosting market confidence in JNJ's oncology portfolio. Analysts expect this could lead to significant revenue growth if the treatment progresses to later trial phases. Overall, JNJ's stock is likely to benefit from this bullish development.